Kenneth Pennington

757 total citations
28 papers, 594 citations indexed

About

Kenneth Pennington is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Surgery. According to data from OpenAlex, Kenneth Pennington has authored 28 papers receiving a total of 594 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 7 papers in Radiology, Nuclear Medicine and Imaging and 6 papers in Surgery. Recurrent topics in Kenneth Pennington's work include Lung Cancer Research Studies (7 papers), Radiopharmaceutical Chemistry and Applications (6 papers) and Neuroendocrine Tumor Research Advances (5 papers). Kenneth Pennington is often cited by papers focused on Lung Cancer Research Studies (7 papers), Radiopharmaceutical Chemistry and Applications (6 papers) and Neuroendocrine Tumor Research Advances (5 papers). Kenneth Pennington collaborates with scholars based in United States and India. Kenneth Pennington's co-authors include L H Einhorn, J. McClean, Seza A. Güleç, Seza Güleç, Rafat Ansari, Yuman Fong, Michael Hall, Roger Tokars, R. Mantravadi and William B. Fisher and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Kenneth Pennington

28 papers receiving 572 citations

Peers

Countries citing papers authored by Kenneth Pennington

Since Specialization

Citations

This map shows the geographic impact of Kenneth Pennington's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenneth Pennington with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenneth Pennington more than expected).

Fields of papers citing papers by Kenneth Pennington

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenneth Pennington. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenneth Pennington. The network helps show where Kenneth Pennington may publish in the future.

Co-authorship network of co-authors of Kenneth Pennington

This figure shows the co-authorship network connecting the top 25 collaborators of Kenneth Pennington. A scholar is included among the top collaborators of Kenneth Pennington based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenneth Pennington. Kenneth Pennington is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pulmonary Langerhans Cell Histiocytosis: Is Marijuana Smoking a Risk Factor? 2020 ·María P. Martín, Kenneth Pennington, Robert Vassallo	1
2	Fractionated radioimmunotherapy with 90Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial 2020 ·UNC Libraries ·Nathan C. Hall, Bert H. O’Neil, (unknown), Michael J. Guarino, John Kauh, Max W. Sung, Daniel Lee, (unknown), Kenneth Pennington, Tanios Bekaii‐Saab, Stanley J. Goldsmith, David V. Gold, Heather Horne, David M. Goldenberg, Arif Sheikh, Aldo N. Serafini, William A. Wegener, (unknown), Alberto J. Montero, Seza A. Güleç	1
3	Phase I study of TH-302, investigational hypoxia-targeted drug, in combination with sunitinib. 2013 ·Journal of Clinical Oncology ·Alexander Starodub, Mohammed Milhem, Kenneth Pennington, Ebenezer A. Kio, Daniel Bruetman, (unknown), (unknown), Stew Kroll	2
4	Fractionated radioimmunotherapy with ⁹⁰ Y‐clivatuzumab tetraxetan and low‐dose gemcitabine is active in advanced pancreatic cancer 2012 ·Cancer ·Allyson J. Ocean, Kenneth Pennington, Michael J. Guarino, Arif Sheikh, Tanios Bekaii‐Saab, Aldo N. Serafini, Daniel Lee, Max W. Sung, Seza Güleç, Stanley J. Goldsmith, (unknown), Michael Holt, Bert H. O’Neil, Nathan C. Hall, Alberto J. Montero, John Kauh, David V. Gold, Heather Horne, William A. Wegener, David M. Goldenberg	64
5	Activity of fractionated radioimmunotherapy (RAIT) with 90Y clivatuzumab tetraxetan (90Y-hPAM4) plus gemcitabine (Gem) in advanced pancreatic cancer (APC): Final results from a two-part study. 2012 ·Journal of Clinical Oncology ·Allyson J. Ocean, Michael J. Guarino, Kenneth Pennington, Gregory M. Springett, Seza A. Güleç, Tanios Bekaii‐Saab, Alberto J. Montero, Edith P. Mitchell, John Kauh, Max W. Sung, David V. Gold, Heather Horne, William A. Wegener, David M. Goldenberg	1
6	The First Documented Case of High-Grade Synovial Cell Sarcoma of the Rectum 2012 ·Journal of the National Comprehensive Cancer Network ·(unknown), Min Yan, (unknown), Kenneth Pennington, (unknown)	4
7	Yttrium-90 Microsphere-selective Internal Radiation Therapy With Chemotherapy (Chemo-SIRT) for Colorectal Cancer Liver Metastases 2012 ·American Journal of Clinical Oncology ·Seza Güleç, Kenneth Pennington, (unknown), (unknown), (unknown), Michael R. Hall, Douglas J. Schwartzentruber	28
8	The prognostic value of functional tumor volume and total lesion glycolysis in patients with colorectal cancer liver metastases undergoing 90Y selective internal radiation therapy plus chemotherapy 2011 ·European Journal of Nuclear Medicine and Molecular Imaging ·Seza A. Güleç, (unknown), (unknown), Kenneth Pennington	65
9	Treatment of Advanced Pancreatic Carcinoma with 90Y-Clivatuzumab Tetraxetan: A Phase I Single-Dose Escalation Trial 2011 ·Clinical Cancer Research ·Seza A. Güleç, Steven J. Cohen, Kenneth Pennington, Lionel S. Zuckier, Ralph J. Hauke, Heather Horne, William A. Wegener, (unknown), David V. Gold, Robert M. Sharkey, David M. Goldenberg	46
10	Activity of fractionated radioimmunotherapy with clivatuzumab tetraxetan combined with low-dose gemcitabine (Gem) in advanced pancreatic cancer (APC). 2011 ·Journal of Clinical Oncology ·Allyson J. Ocean, (unknown), Kenneth Pennington, Alberto J. Montero, Tanios Bekaii‐Saab, (unknown), Nick Teoh, David V. Gold, William A. Wegener, David M. Goldenberg	5
11	Preoperative Y-90 microsphere selective internal radiation treatment for tumor downsizing and future liver remnant recruitment: a novel approach to improving the safety of major hepatic resections 2009 ·World Journal of Surgical Oncology ·Seza Güleç, Kenneth Pennington, Michael Hall, Yuman Fong	55
12	Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab for Treatment of Relapsed Immune Thrombocytopenia (ITP). 2009 ·Blood ·Mansoor N. Saleh, Howard A. Liebman, Zale P. Bernstein, (unknown), James B. Bussel, (unknown), Charles M. Farber, (unknown), Thomas M. Cosgriff, Kenneth Pennington, Heather Horne, Nick Teoh, (unknown), William A. Wegener, David M. Goldenberg	4
13	Phase II trial of multiagent chemotherapy combined with Y-90 microsphere selective internal radiation therapy (chemo-SIRT) in patients with colorectal cancer liver metastases 2008 ·Journal of Clinical Oncology ·Kenneth Pennington, Seza A. Güleç, (unknown), (unknown), James Wheeler, Douglas J. Schwartzentruber	1
14	Phase II study of low-dose topotecan in myelodysplastic syndromes: a Hoosier Oncology Group (HOG) study 2003 ·Leukemia Research ·Daniel A. Vaena, Paul Walker, Kenneth Pennington, (unknown), (unknown), Constantin T. Yiannoutsos, Carol Young, (unknown), Larry D. Cripe	4
15	Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: a Hoosier Oncology Group protocol. 1995 ·Journal of Clinical Oncology ·Charles D. Blanke, Rafat Ansari, R. Mantravadi, R Gonin, Roger Tokars, William B. Fisher, Kenneth Pennington, (unknown), (unknown), Michael E. Miller	111
16	A Phase II Trial of Vinblastine Plus Dipyridamole in Advanced Renal Cell Carcinoma A Hoosier Oncology Group Study 1994 ·American Journal of Clinical Oncology ·Brian R. Murphy, (unknown), Kenneth Pennington, William W. Grosh, Patrick J. Loehrer	16
17	Etoposide, Ifosfamide, and Cisplatin in Extensive Small Cell Lung Cancer 1992 ·Cancer ·Patrick J. Loehrer, (unknown), Rafat Ansari, J. Glenn Songer, Kenneth Pennington, Lawrence H. Einhorn	26
18	Title of paper: A phase III study of thoracic radiation with or without concurrent cisplatin chemotherapy in locoregional unresectable non-small cell carcinoma of the lung. a hoosier oncology group protocol 1991 ·International Journal of Radiation OncologyBiologyPhysics ·Roger Tokars, Rafat Ansari, R. Mantravadi, (unknown), (unknown), Kenneth Pennington, Thomas P. O’Connor, (unknown), Michelle Miller	6
19	Phase II trial of daily oral VP-16 in refractory small cell lung cancer: a Hoosier Oncology Group study. 1990 ·PubMed ·L H Einhorn, Kenneth Pennington, J. McClean	72
20	Etoposide and Split-Dose Cisplatin in Bronchogenic Carcinoma 1988 ·American Journal of Clinical Oncology ·Richard C. Lauer, William B. Fisher, Kenneth Pennington, Rafat Ansari, Lawrence H. Einhorn, Patrick J. Loehrer	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact